Clinical Trial Update: Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing vaccine therapy plus sargramostim and interleukin-2 versus nilutamide alone in prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Leukine (sargramostim) (sargramostim)
• Nilandron (nilutamide) (nilutamide)
• Proleukin (interleukin-2) (aldesleukin)
• Vaccine therapy

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED